Speaking at Artemis' investment roadshow
AstraZeneca is top holding at 7.4%
Rob Drijkoningen, global co-head of emerging markets debt at Neuberger Berman, takes a closer look at the drivers of the EM recovery.
Corporate backdrop favourable
The casual observer of recent dividend trends in the UK may be forgiven for believing the income outlook has improved dramatically.
Managers from Investment Week's US Market Focus discuss the drivers and risks for the asset class.
Scientific breakthroughs the key driver
Economies under Trump's 'radar'